Biolexis and Akston Biosciences Announce Encouraging Top-Line Results from Phase II/III Trial of their Thermostable 2nd Gen COVID-19 Vaccine

BEVERLY, Mass. & BANGALORE, India–(BUSINESS WIRE)– #AKS452–Biolexis, Akston Biosciences announce top-line results: 91% seroconversion rate from Phase II/III trial of their thermostable COVID-19 vaccine.
Click here to view original post